发明授权
US08008274B2 P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis
有权
用于治疗鼻窦炎的P1-（2'-脱氧胞苷5' - ）P4-（尿苷5' - ）四磷酸盐，四（碱金属）盐）
- 专利标题： P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis
- 专利标题（中）： 用于治疗鼻窦炎的P1-（2'-脱氧胞苷5' - ）P4-（尿苷5' - ）四磷酸盐，四（碱金属）盐）
-
申请号： US12436679申请日： 2009-05-06
-
公开(公告)号： US08008274B2公开(公告)日： 2011-08-30
- 发明人: Benjamin R. Yerxa , Ward M. Peterson , Janet L. Rideout , William Pendergast
- 申请人： Benjamin R. Yerxa , Ward M. Peterson , Janet L. Rideout , William Pendergast
- 申请人地址： US NJ Whitehouse Station
- 专利权人： Inspire Pharmaceuticals, Inc.
- 当前专利权人： Inspire Pharmaceuticals, Inc.
- 当前专利权人地址： US NJ Whitehouse Station
- 代理机构： Perkins Coie LLP
- 代理商 Viola T. Kung
- 主分类号： A61K31/7072
- IPC分类号： A61K31/7072 ; C07H19/10
摘要：
The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The present invention also provides a method of treating cystic fibrosis. The present invention also provides a method of treating sinusitis. The present invention further provides P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.
公开/授权文献
信息查询
IPC分类:
